Augmented anti-arthritic effect of soluble RAGE tagged with an acidic oligopeptide
| Project/Area Number |
20790150
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Hokuriku University |
|---|
Principal Investigator |
TAKAHASHI Tatsuo Hokuriku University, 薬学部, 助教 (50445904)
|
|---|
| Project Period (FY) |
2008 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | ドラッグデリバリー / 関節リウマチ / 可溶型RAGE / 酸性オリゴペプチド / ドラッグデリバリーシステム / Receptor for advanced glycation endproducts / Receptor for advanced glycation end products |
|---|
| Research Abstract |
Endogenous secretory receptor for advanced glycation endproducts (esRAGE) can act as decoy receptor of HMGB1 involved in progression of rheumatoid arthritis. Tagging with an acidic oligopeptide (AcOP), bone-targeting carrier, was enable to augment bone distribution of esRAGE, while retaining function as decoy receptor. Moreover AcOP-tagged esRAGE retained in bone at least one week after intravenous injection. In rheumatoid arthritis model mice, weekly injection of AcOP-tagged esRAGE attenuated swelling of four limbs more effectively than untagged esRAGE. Thus bone-targeting system with an acidic oligopeptide is applicable to esRAGE as potential agent of rheumatoid arthritis.
|
Report
(4 results)
Research Products
(14 results)
